Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.64 |
| ▸ | NOS1 | P29475 | 2/20 | 0.55 |
| ▸ | NOS2 | P35228 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.52 |
| ▸ | HRH1 | P35367 | 4/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.52 |
| ▸ | DRD3 | P35462 | 3/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674639 | 0.92 | ATAD2 (0.68) | ATAD2NOS1NOS2SLC6A4HRH1 | |
| SCHEMBL14049722 | 0.88 | ATAD2 (0.59) | ATAD2NOS1NOS2SLC6A4HRH1 | |
| SCHEMBL2676076 | 0.87 | ATAD2 (0.65) | ATAD2NOS1NOS2SLC6A4HRH1 | |
| SCHEMBL2791880 | 0.87 | ATAD2 (0.50) | ATAD2NOS1NOS2SLC6A4HRH1 | |
| SCHEMBL2674744 | 0.84 | ATAD2 (0.57) | ATAD2NOS1NOS2SLC6A4HRH1 | |
| SCHEMBL14049720 | 0.82 | ATAD2 (0.65) | ATAD2CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL16453538 | 0.82 | ATAD2 (0.78) | ATAD2NOS1NOS2CHRM1CYP2D6 | |
| SCHEMBL2674741 | 0.82 | ATAD2 (0.68) | ATAD2NOS1NOS2CHRM1CYP2D6 | |
| SCHEMBL2675638 | 0.80 | GRIN1 (0.54) | NOS1NOS2SLC6A4HRH1CHRM1 | |
| SCHEMBL8510313 | 0.80 | ATAD2 (0.50) | ATAD2NOS1NOS2SLC6A4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| WO-2008116308-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS1, NOS2, NOS3 | ATAD2 1833/4885NOS1 1/4885NOS2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.